BRAND REFERENCE
Mounjaro® vs Ozempic® — Tirzepatide vs Semaglutide, Molecule by Molecule
The most common comparison in this category is really a comparison of two molecules. Here is what actually differs — and what we do and do not supply.
WHAT WE DO NOT SUPPLY
We do not sell Mounjaro®, Ozempic® or any prescription medicine, and we are not a pharmacy. Our tirzepatide is a research compound for laboratory use only — not a medicine, and not for human or veterinary use.
LIVING WATER LABS · RESEARCH-GRADE
Research-grade GLP compounds from LWL
Live price and stock. Lyophilised research vials, Janoshik HPLC purity certificates, dispatched from Johannesburg. For laboratory research use only.
The molecule behind Mounjaro® is tirzepatide. LWL supplies research-grade tirzepatide in 30 mg and 60 mg vials — alongside retatrutide and eloralintide — for laboratory research.
Retatrutide 30mg
GLP-1 / GIP / glucagon receptor triple agonist
VIEW RESEARCH COMPOUND →
Retatrutide 60mg
GLP-1 / GIP / glucagon receptor triple agonist
VIEW RESEARCH COMPOUND →
Tirzepatide 30mg
GIP / GLP-1 receptor dual agonist
VIEW RESEARCH COMPOUND →
Tirzepatide 60mg
GIP / GLP-1 receptor dual agonist
VIEW RESEARCH COMPOUND →
Eloralintide
Selective amylin receptor agonist
VIEW RESEARCH COMPOUND →
Retatrutide certificate summary →Tirzepatide certificate summary →
Mounjaro® is Eli Lilly’s tirzepatide; Ozempic® is Novo Nordisk’s semaglutide. Both are once-weekly injectable incretin medicines, but they are built on different pharmacology. Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual agonist, acting on the GIP receptor as well as the GLP-1 receptor — a single peptide engineered to engage both incretin pathways.
Each has its own clinical trial programme: the SURPASS and SURMOUNT trials for tirzepatide, and the SUSTAIN and STEP trials for semaglutide. The two molecules have also been compared head to head in a dedicated trial, SURMOUNT-5. Those trials studied the manufacturers’ medicines in clinical participants; their findings belong to those products and are not a description of any research vial.
Of the two molecules, tirzepatide is the one we hold — as a research-grade lyophilised vial for laboratory use, with a Janoshik HPLC purity report. It is not Mounjaro®, not a substitute for it, and not for use in a person. We do not stock semaglutide.
Side by side
Molecule
Mounjaro®: tirzepatide · Ozempic®: semaglutide
Research tirzepatide and retatrutide (no semaglutide)
Receptors
Tirzepatide: GIP + GLP-1 · Semaglutide: GLP-1
Retatrutide: GLP-1 + GIP + glucagon
Schedule
Both once-weekly injectable pens
Lyophilised research vials, reconstituted in the lab
Trial programmes
SURPASS / SURMOUNT (tirzepatide) · SUSTAIN / STEP (semaglutide) · SURMOUNT-5 head to head
Janoshik HPLC purity report per batch
Do we supply it
No — neither brand
Yes, as research vials, for laboratory use only
LWL research GLP compounds compared
Receptor pharmacology, vial size and price per milligram — live. Pre-order prices include the 10% pre-order saving. Research use only.
| Compound | Receptor targets | Vial | Price | Per mg | Status |
|---|---|---|---|---|---|
| Retatrutide 30mgLY3437943 | GLP-1 / GIP / glucagon receptor triple agonist | 30 mg | R1,574 | R52.5/mg | PRE-ORDER · SHIPS 15 OCT · 10% OFF |
| Retatrutide 60mgLY3437943 | GLP-1 / GIP / glucagon receptor triple agonist | 60 mg | R3,399 | R56.6/mg | IN STOCK · SAME-DAY DISPATCH |
| Tirzepatide 30mgLY3298176 | GIP / GLP-1 receptor dual agonist | 30 mg | R1,259 | R42.0/mg | PRE-ORDER · SHIPS 15 OCT · 10% OFF |
| Tirzepatide 60mgLY3298176 | GIP / GLP-1 receptor dual agonist | 60 mg | R2,429 | R40.5/mg | PRE-ORDER · SHIPS 15 OCT · 10% OFF |
| EloralintideLY3841136 | Selective amylin receptor agonist | 15 mg | R2,699 | R180/mg | PRE-ORDER · SHIPS 15 OCT · 10% OFF |
Also searched as
These are the short forms, spellings and code designations people use for the same thing. They are listed so the terminology is unambiguous, not because any of them names a different product.
Questions
What is the main difference between Mounjaro® and Ozempic®?
The molecule. Mounjaro® contains tirzepatide, which acts on two receptors (GIP and GLP-1). Ozempic® contains semaglutide, which acts on one (GLP-1). Both are prescription medicines; only a clinician can advise on either.
Have they been compared directly?
Yes — the SURMOUNT-5 trial compared tirzepatide and semaglutide head to head. Its results describe the manufacturers’ medicines in trial participants, not any research compound.
Do you sell either?
No. We supply tirzepatide and retatrutide as research-grade vials for laboratory research only. We do not stock semaglutide, and we do not sell any branded medicine.
CONTINUE TO THE RESEARCH COMPOUNDS
Read next
Every compound we supply is sold strictly for laboratory research purposes only. Not for human or veterinary use, and not a medicine. Nothing on this page is medical advice, a dosing instruction or a claim of any outcome.
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Living Water Labs is not affiliated with, endorsed by or connected to either company, and does not supply any of these medicines. The names are used here only to identify what they are.